DARA BioSciences, Inc. Announces Appointment of New Director to Board
28 February 2008 - 8:15AM
PR Newswire (US)
RALEIGH, N.C., Feb. 27 /PRNewswire-FirstCall/ -- DARA
BioSciences(TM) (NASDAQ:DARA) announced today the appointment of
Haywood D. Cochrane, Jr. to the Board of Directors. Mr. Cochrane
was appointed to fill a Board vacancy and will serve on the
Company's Audit and Compensation Committees. The appointment was
effective February 21, 2008. In making the announcement DARA's
Board Chairman, Richard Franco, Sr., commented, "We are pleased
that Haywood has joined us as a Director. His vast knowledge and
successful experience in the healthcare industry will further
strengthen DARA's already skilled Board." Mr. Cochrane is currently
Vice Chairman and a Director of I-trax, Inc. (AMEX:DMX), a publicly
traded, total population health management and productivity
company. Mr. Cochrane has previously served as a Director of seven
other publicly-traded companies. About DARA BioSciences, Inc. DARA
BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based
development-stage pharmaceutical company that acquires promising
therapeutic molecules and medical technologies directly or through
investment in established companies. DARA focuses its therapeutic
development efforts on small molecules from late preclinical
development through phase 2 clinical trials. DARA is developing a
portfolio of therapeutic candidates for neuropathic pain, metabolic
diseases including type 2 diabetes, dyslipidemia and dermatological
disorders. DARA has licensed promising drug development candidates
from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals
Corporation, Massachusetts General Hospital and Nuada LLC. For more
information please contact the Company at 919-872-5578 or visit our
web site at http://www.darabio.com/. All statements in this news
release that are not historical are forward-looking statements
within the meaning of the Securities Exchange Act of 1934 as
amended. Such forward-looking statements are subject to factors
that could cause actual results to differ materially for DARA from
those projected. Those factors include risks and uncertainties
relating to the company's ability to develop and bring new products
to market as anticipated, the current regulatory environment in
which the company develops and sells its products, the market
acceptance of those products, dependence on partner, successful
performance under collaborative and other commercial agreements,
competition, the strength of DARA's intellectual property, the
intellectual property of others and other risk factors identified
in the documents DARA has filed, or will file, with the Securities
and Exchange Commission. Copies of DARA's filings with the SEC may
be obtained from the SEC Internet site at http://www.sec.gov/. DARA
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DARA's expectations with
regard thereto or any change in events, conditions, or
circumstances on which any such statements are based. DARA
BioSciences and the DARA logo are trademarks of DARA BioSciences,
Inc. DATASOURCE: DARA BioSciences, Inc. CONTACT: John C. Thomas,
Jr., Chief Financial Officer, +1-919-872-5578, or Lynn H. Morris,
Sr. Manager, Investor Relations & Corporate Operations,
+1-919-872-5578, both of DARA BioSciences, Inc. Web site:
http://www.darabio.com/
Copyright
Doubleline Multi sector ... (AMEX:DMX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Doubleline Multi sector ... (AMEX:DMX)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Doubleline Multi sector Income ETF (American Stock Exchange): 0 recent articles
More I-Trax, News Articles